Christophe Bourdon
Directeur/Membre du Conseil chez SWEDISH ORPHAN BIOVITRUM AB
Provenance du réseau au premier degré de Christophe Bourdon
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 20 | |
| Public Company | Pharmaceuticals: Major | 7 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Christophe Bourdon via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member President | |
Gambro AB
 Gambro AB Medical SpecialtiesHealth Technology Gambro AB engages in the development and manufacturing of dialysis equipment and blood purification products. It provides products and therapies for kidney and liver dialysis, myeloma kidney therapy, and other extracorporeal therapies for chronic and acute patients. The firm offers products for hemodialysis, acute care, myeloma kidney therapy, and vascular access and water systems. The company was founded by Holger Crafoord in 1964 and is headquartered in Lund, Sweden. | Medical Specialties | Director/Board Member Chief Executive Officer Director/Board Member | |
Takeda Pharmaceuticals International AG
 Takeda Pharmaceuticals International AG Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals International GmbH develops, manufactures, and distributes pharmaceutical products. It offers medicines in therapeutic areas, such as, cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine, and vaccines. The firm also provides packaging, development, contract manufacturing and quality control services. Takeda Pharmaceuticals International was founded in 1874 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer President Corporate Officer/Principal | |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Financial Conglomerates | Chief Tech/Sci/R&D Officer Chief Executive Officer Chief Operating Officer | |
Swedish Orphan Biovitrum, Inc.
 Swedish Orphan Biovitrum, Inc. Pharmaceuticals: MajorHealth Technology Swedish Orphan Biovitrum, Inc. operates as an international rare disease company providing access to treatments that make a significant difference for people with rare diseases. Its business areas include haemophilia, immunology and specialty care. The company is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Nycomed AB
 Nycomed AB Pharmaceuticals: MajorHealth Technology Nycomed AB With a broad portfolio of products and a powerful pipeline, they work in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management. Nycomed engaged in all aspects of a product's life, from research and development to customer relations. They also work closely with innovative research-based companies, constantly looking for products with real promise for patients. They believe that everything do matters to someone. So they work carefully to make sure they get what they do right. They focus on results and respond quickly to the needs of patients and healthcare providers, giving them the best possible experience from working with clients. By doing this, they can achieve vision of being the preferred pharmaceutical company. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal General Counsel | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Sales & Marketing Sales & Marketing | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Doctorate Degree | |
| MEDA AB | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
| ABLYNX | Biotechnology | Chairman Director/Board Member | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| INVESTOR AB | Financial Conglomerates | Director of Finance/CFO Corporate Officer/Principal | |
| Stockholm School of Economics | College/University | Director/Board Member Graduate Degree | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
| QIAGEN N.V. | Medical Specialties | Director/Board Member Chairman | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Investor Relations Contact | |
| OBSEVA SA | Pharmaceuticals: Major | Chairman | |
| LYSOGENE | Miscellaneous Commercial Services | Chairman | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Abcd Ltd. | Director/Board Member | ||
ENYO Pharma SA
 ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Chairman | |
Dr. Reddy's Research & Development BV
 Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
| BONESUPPORT HOLDING AB | Medical Specialties | Director/Board Member | |
Acino Pharma AG
 Acino Pharma AG Pharmaceuticals: MajorHealth Technology Acino Pharma AG engages in the development, production, and distribution of chemical and pharmaceutical products. It also acquires, manages, and sells participating interests in firms, real estate, and intellectual property rights. The company was founded in 1961 and is headquartered in Liesberg, Switzerland. | Pharmaceuticals: Major | Chairman | |
| Yale University | College/University | Graduate Degree | |
Starid Holding 1 AB
 Starid Holding 1 AB Real Estate DevelopmentFinance Part of Astrid Luxembourg SARL, Starid Holding 1 AB engages in renting of industrial premises. The company is based in Malmö, Sweden. | Real Estate Development | Director/Board Member | |
| INNATE PHARMA | Pharmaceuticals: Major | Corporate Officer/Principal | |
STJ Advisors LLP
 STJ Advisors LLP Investment ManagersFinance STJ Advisors LLP provides capital markets advisory services. The private company is based in London, UK and has subsidiaries in Hong Kong. The British company was founded in 2008 by John James Moore St. John. | Investment Managers | Corporate Officer/Principal | |
| MORGAN STANLEY | Investment Managers | Corporate Officer/Principal | |
| ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member | |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Chief Executive Officer |
Statistiques
Internationale
| Suède | 16 |
| France | 8 |
| Pays-Bas | 7 |
| Etats-Unis | 6 |
| Royaume-Uni | 6 |
Sectorielle
| Health Technology | 34 |
| Finance | 9 |
| Commercial Services | 4 |
| Consumer Services | 4 |
Opérationnelle
| Director/Board Member | 166 |
| Chairman | 53 |
| Independent Dir/Board Member | 50 |
| Corporate Officer/Principal | 48 |
| Chief Executive Officer | 28 |
Relations les plus connectées
| Insiders | |
|---|---|
| Sven Håkan Björklund | 46 |
| Bo Jesper Hansen | 34 |
| Martijn Kleijwegt | 33 |
| Anders Hedegaard | 30 |
| Rémi Droller | 29 |
| Catherine Moukheibir | 29 |
| Sven Anders Ullman | 19 |
| Guido Oelkers | 19 |
| Henrik Stenqvist | 16 |
| Staffan Schüberg | 15 |
| Helena Ildiko Saxon | 14 |
| Annette Clancy | 10 |
| Per Richard Torbjörn Hallberg | 10 |
| Pablo de Mora | 7 |
| Lena Bjurner | 7 |
- Bourse
- Insiders
- Christophe Bourdon
- Connexions Sociétés
